Vernakalant Cleared in EU for Conversion of AF to Sinus Rhythm

September 09, 2010

September 9, 2010 (London, United Kingdom) — A novel intravenous drug, vernakalant (Brinavess, Merck/Cardiome Pharma), has been approved in the European Union, Iceland, and Norway for the rapid conversion of recent-onset atrial fibrillation (AF) to sinus rhythm in adults: for nonsurgical patients with AF of duration seven days or less and for post–cardiac-surgery patients with AF of duration three days or less [1,2].

As reported by heartwire , vernakalant is the first in a class of new pharmacologic agents developed for the acute conversion of AF and works by blocking early-activating K+ channels and frequency-dependent Na+ channels.

Regulatory approval is based on the results of four trials: AVRO, reported at the Heart Rhythm Society meeting this year, in which vernakalant was shown to be more effective than an active comparator, amiodarone, for the rapid conversion of AF to sinus rhythm and to yield a higher rate of symptom relief; and three randomized, double-blind, placebo-controlled studies, ACT I, ACT II, and ACT III.

Vernakalant is still not approved in the US, however, despite an FDA advisory committee having voted to recommend approval almost three years ago, in December 2007; the agency requested more information on the drug, which is to be marketed in North America by Cardiome and Astellas.

Guy Cipriani (Cardiome, Vancouver, BC) told heartwire that an additional phase 3 study, ACT V, was initiated in October 2009 to address the FDA's concerns about vernakalant, which were detailed in an approvable letter dated August 2008 [3]. Act V is expected to be completed in the first half of 2011, he says.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.